Benzinga

NOVEMBER 30, 2023

AbbVie (NYSE: ABBV ) has announced an acquisition of Immunogen (NASDAQ: IMGN ) that is expected to be completed 2024-H1. Under the terms of the agreement, AbbVie has agreed to give Immunogen $10.10 About The Companies Involved AbbVie is a pharmaceutical firm with a strong exposure to immunology and oncology.

59

59

Benzinga

NOVEMBER 30, 2023

AbbVie Inc (NYSE: ABBV ) has agreed to acquire ImmunoGen Inc (NASDAQ: IMGN ) and its flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer. Full story available on Benzinga.com

64

64

Law 360 M&A

JANUARY 8, 2024

A shareholder alleges that ImmunoGen Inc. directors and advisers significantly undervalued the company while preparing to sell to AbbVie Inc., including by failing to consider the $1.6 billion in projected revenue from a new ovarian cancer drug, according to a suit filed Monday.

75

75

Benzinga

MAY 30, 2023

May 30, 2023 (GLOBE NEWSWIRE) -- Morphogenesis, Inc. Morphogenesis"), a privately-held Phase 2/3 clinical-stage biotechnology company developing novel personalized cancer vaccines and tumor microenvironment modulators to overcome resistance to current immunotherapies, and CohBar, Inc. About Morphogenesis, Inc. TAMPA, Fla.

Technology 40

Technology Marketability 40

Benzinga

NOVEMBER 16, 2023

-- The combined company will operate as Q32 Bio Inc., 16, 2023 (GLOBE NEWSWIRE) -- Q32 Bio Inc., a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Homology Medicines, Inc. -- The combined company will operate as Q32 Bio Inc., and BEDFORD, Mass.,

Finance 45

Finance Technology 45